Industry
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Total Trials
5
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed trials have results
Key Signals
1 recruiting2 with results
Enrollment Performance
Analytics
Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT06226883Phase 2Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Role: lead
NCT06977880Phase 1Completed
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
Role: lead
NCT05291689Phase 2Completed
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Role: lead
NCT05611671Phase 2Active Not Recruiting
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Role: lead
NCT04580745Phase 1Completed
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
Role: lead
All 5 trials loaded